Predictions 2022: The pandemic and beyond: How the pharma industry is shaping up for the future
In the coming year, the pharma industry will continue to reimagine itself while driving growth and boosting value.
pharmaceuticals
December 2021
October 2021
July 2021
June 2021
May 2021
April 2021
March 2021
55 Indian pharma cos capable of mRNA vaccines
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
Piramal demerges pharma business, to list on stock exchanges
Restructuring to simplify corporate structure, create two separate listed entities.
Watch: Cipla on Covid and beyond
In the latest episode of Biz Buzz, Umang Vohra, global MD & CEO, Cipla, talks about the paradigm shift in the Indian pharma industry, and Cipla's plans for booster shots of Covid-19 vaccine.
Syngene’s winning formula
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
The soul of India’s PLI schemes
The production-linked incentive schemes seek to reimagine the dreams of the Indian economy. It will, of course, take a few years to completely evaluate the impact of them.
Families to the fore in healthcare
The healthcare sector is dominated by family-run firms, some of which have come into prominence in the past year.
The Ellas of Bharat Biotech: The gift of the jab
Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.
Reimagining Indian pharma
India’s pharma industry is reimagining itself. This is not just borne out of the necessities brought forth by the pandemic, but is a blueprint to thrive and to succeed in this new world.
This decade will mirror the ’90s: Kenneth Andrade
The veteran of the investment industry argues that this decade will witness an export-led growth. And while IT and pharma would rule the economy, other smaller industries, too, will jostle to rise up.
